Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
In recent years, immunotherapy has emerged as a form of treatment that can lead to robust
responses in a subset of patients. PD-1 inhibitor plus chemotherapy showed prolonged survival
in NSCLC by the study of KEYNOTE 024, KEYNOTE 189 etc. Thus, this study combines
immunotherapeutic agent PD-1 inhibitor with an ant-angiogenic agent, bevacizumab, and double
platinum therapy (carboplatin/cisplatin and pemetrexed).